secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002086
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics prioritizes MT-601 for CAR T-relapsed lymphoma, discontinues patient-specific AML program
--------------------------------------------------------------------------------

- MT-601 for DLBCL patients who relapsed after CAR T: first APOLLO participant maintained complete response at 6 months.
- Patient-specific AML program (ARTEMIS) discontinued due to manufacturing delays; shift to ready-to-use MT-401 from healthy donors.
- Non-dilutive funding secured for off-the-shelf AML program; cash runway extended into Q4 2025.
- Pancreatic cancer Phase 1 IND cleared but advancement pending additional non-dilutive funding.
- MultiTAA T cell therapies shown safe in over 200 patients; no treatment-related adverse events in APOLLO or ARTEMIS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924002086/0001104659-24-002086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465924002086/tm242285d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer